vs
渤健（BIIB）与Northern Trust（NTRS）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是Northern Trust的1.0倍（$2.3B vs $2.2B），Northern Trust净利率更高（23.7% vs -2.1%，领先25.9%），Northern Trust同比增速更快（13.8% vs -7.1%），过去两年Northern Trust的营收复合增速更高（37.8% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
Northern Trust是总部位于美国伊利诺伊州芝加哥的专业金融服务企业，主要服务对象包括各类企业、机构投资者以及超高净值个人客户，是美国规模最大、持续运营历史最悠久的银行机构之一。截至2025年12月末，其管理资产规模达1.8万亿美元，托管资产规模达14.9万亿美元。
BIIB vs NTRS — 直观对比
营收规模更大
BIIB
是对方的1.0倍
$2.2B
营收增速更快
NTRS
高出20.9%
-7.1%
净利率更高
NTRS
高出25.9%
-2.1%
两年增速更快
NTRS
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.2B |
| 净利润 | $-48.9M | $525.5M |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | — |
| 净利率 | -2.1% | 23.7% |
| 营收同比 | -7.1% | 13.8% |
| 净利润同比 | -118.3% | 13.0% |
| 每股收益（稀释后） | $-0.35 | $2.71 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBNTRS
| Q1 26 | — | $2.2B | ||
| Q4 25 | $2.3B | $1.3B | ||
| Q3 25 | $2.5B | $1.3B | ||
| Q2 25 | $2.6B | $1.2B | ||
| Q1 25 | $2.4B | $1.2B | ||
| Q4 24 | $2.5B | $1.2B | ||
| Q3 24 | $2.5B | $1.2B | ||
| Q2 24 | $2.5B | $1.2B |
净利润BIIBNTRS
| Q1 26 | — | $525.5M | ||
| Q4 25 | $-48.9M | $466.0M | ||
| Q3 25 | $466.5M | $457.6M | ||
| Q2 25 | $634.8M | $421.3M | ||
| Q1 25 | $240.5M | $392.0M | ||
| Q4 24 | $266.7M | $455.4M | ||
| Q3 24 | $388.5M | $464.9M | ||
| Q2 24 | $583.6M | $896.1M |
毛利率BIIBNTRS
| Q1 26 | — | — | ||
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — |
营业利润率BIIBNTRS
| Q1 26 | — | — | ||
| Q4 25 | -2.5% | 48.5% | ||
| Q3 25 | 22.0% | 49.0% | ||
| Q2 25 | 28.1% | 45.9% | ||
| Q1 25 | 12.8% | 43.0% | ||
| Q4 24 | 11.9% | 48.6% | ||
| Q3 24 | 18.3% | 50.2% | ||
| Q2 24 | 28.3% | — |
净利率BIIBNTRS
| Q1 26 | — | 23.7% | ||
| Q4 25 | -2.1% | 35.6% | ||
| Q3 25 | 18.4% | 36.2% | ||
| Q2 25 | 24.0% | 34.2% | ||
| Q1 25 | 9.9% | 32.3% | ||
| Q4 24 | 10.9% | 37.3% | ||
| Q3 24 | 15.8% | 38.9% | ||
| Q2 24 | 23.7% | 76.8% |
每股收益（稀释后）BIIBNTRS
| Q1 26 | — | $2.71 | ||
| Q4 25 | $-0.35 | $2.42 | ||
| Q3 25 | $3.17 | $2.29 | ||
| Q2 25 | $4.33 | $2.13 | ||
| Q1 25 | $1.64 | $1.90 | ||
| Q4 24 | $1.82 | $2.25 | ||
| Q3 24 | $2.66 | $2.22 | ||
| Q2 24 | $4.00 | $4.34 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | $6.3B | $2.9B |
| 股东权益账面价值 | $18.3B | $13.0B |
| 总资产 | $29.4B | $174.6B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.22× |
8季度趋势，按日历期对齐
总债务BIIBNTRS
| Q1 26 | — | $2.9B | ||
| Q4 25 | $6.3B | — | ||
| Q3 25 | $6.3B | — | ||
| Q2 25 | $6.3B | — | ||
| Q1 25 | $4.5B | — | ||
| Q4 24 | $6.3B | — | ||
| Q3 24 | $4.5B | — | ||
| Q2 24 | $6.3B | — |
股东权益BIIBNTRS
| Q1 26 | — | $13.0B | ||
| Q4 25 | $18.3B | $13.0B | ||
| Q3 25 | $18.2B | $13.0B | ||
| Q2 25 | $17.6B | $12.9B | ||
| Q1 25 | $17.0B | $12.9B | ||
| Q4 24 | $16.7B | $12.8B | ||
| Q3 24 | $16.4B | $12.7B | ||
| Q2 24 | $15.9B | $12.7B |
总资产BIIBNTRS
| Q1 26 | — | $174.6B | ||
| Q4 25 | $29.4B | $177.1B | ||
| Q3 25 | $29.2B | $170.3B | ||
| Q2 25 | $28.3B | $171.9B | ||
| Q1 25 | $28.0B | $165.1B | ||
| Q4 24 | $28.0B | $155.5B | ||
| Q3 24 | $28.3B | $155.8B | ||
| Q2 24 | $26.8B | $156.8B |
负债/权益比BIIBNTRS
| Q1 26 | — | 0.22× | ||
| Q4 25 | 0.34× | — | ||
| Q3 25 | 0.35× | — | ||
| Q2 25 | 0.36× | — | ||
| Q1 25 | 0.27× | — | ||
| Q4 24 | 0.38× | — | ||
| Q3 24 | 0.28× | — | ||
| Q2 24 | 0.40× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | — |
| 自由现金流经营现金流 - 资本支出 | $468.0M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $2.1B | — |
8季度趋势，按日历期对齐
经营现金流BIIBNTRS
| Q1 26 | — | — | ||
| Q4 25 | $511.9M | $388.4M | ||
| Q3 25 | $1.3B | $525.8M | ||
| Q2 25 | $160.9M | $1.9B | ||
| Q1 25 | $259.3M | $2.7B | ||
| Q4 24 | $760.9M | $-2.6B | ||
| Q3 24 | $935.6M | $611.1M | ||
| Q2 24 | $625.8M | $3.0B |
自由现金流BIIBNTRS
| Q1 26 | — | — | ||
| Q4 25 | $468.0M | $355.6M | ||
| Q3 25 | $1.2B | $509.4M | ||
| Q2 25 | $134.3M | $1.9B | ||
| Q1 25 | $222.2M | $2.7B | ||
| Q4 24 | $721.6M | $-2.7B | ||
| Q3 24 | $900.6M | $585.4M | ||
| Q2 24 | $592.3M | $3.0B |
自由现金流率BIIBNTRS
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 27.2% | ||
| Q3 25 | 48.4% | 40.3% | ||
| Q2 25 | 5.1% | 150.8% | ||
| Q1 25 | 9.1% | 225.5% | ||
| Q4 24 | 29.4% | -218.9% | ||
| Q3 24 | 36.5% | 48.9% | ||
| Q2 24 | 24.0% | 254.7% |
资本支出强度BIIBNTRS
| Q1 26 | — | — | ||
| Q4 25 | 1.9% | 2.5% | ||
| Q3 25 | 1.8% | 1.3% | ||
| Q2 25 | 1.0% | 1.0% | ||
| Q1 25 | 1.5% | 1.0% | ||
| Q4 24 | 1.6% | 3.3% | ||
| Q3 24 | 1.4% | 2.1% | ||
| Q2 24 | 1.4% | 1.8% |
现金转化率BIIBNTRS
| Q1 26 | — | — | ||
| Q4 25 | — | 0.83× | ||
| Q3 25 | 2.73× | 1.15× | ||
| Q2 25 | 0.25× | 4.44× | ||
| Q1 25 | 1.08× | 7.01× | ||
| Q4 24 | 2.85× | -5.79× | ||
| Q3 24 | 2.41× | 1.31× | ||
| Q2 24 | 1.07× | 3.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
NTRS
| Trust, Investment and Other Servicing Fees | $1.3B | 61% |
| Other | $871.8M | 39% |
